The effects of saxagliptin on cardiac structure and function using cardiac MRI (SCARF)

Sandhu, P.; Ong, Jann Patrick; Garg, Vinay; Altaha, Mustafa A; Bello, Olubenga; Singal, Sewa R.; Verma, Subodh; Yan, Andrew T.; Connelly, Kim A.

doi:10.1007/s00592-020-01661-y

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Derived from these results, saxagliptin is contraindicated in patients with T2DM and HF [ 7 , 60 ]. Interestingly, an observational cohort including a few patients with T2DM did not observe any detrimental change in LV function or structure, as assessed by cardiac magnetic resonance imaging (CMR), when saxagliptin was added in the conventional treatment for 6 months [ 61 ].…”

Section: Dpp-4 Inhibitorsmentioning

confidence: 99%

Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review

Nikolaidou,

Ventoulis,

Karakoulidis

et al. 2024

Medicina

View full text Add to dashboard Cite

Over the last few years, given the increase in the incidence and prevalence of both type 2 diabetes mellitus (T2DM) and heart failure (HF), it became crucial to develop guidelines for the optimal preventive and treatment strategies for individuals facing these coexisting conditions. In patients aged over 65, HF hospitalization stands out as the predominant reason for hospital admissions, with their prognosis being associated with the presence or absence of T2DM. Historically, certain classes of glucose-lowering drugs, such as thiazolidinediones (rosiglitazone), raised concerns due to an observed increased risk of myocardial infarction (MI) and cardiovascular (CV)-related mortality. In response to these concerns, regulatory agencies started requiring CV outcome trials for all novel antidiabetic agents [i.e., dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2is)] with the aim to assess the CV safety of these drugs beyond glycemic control. This narrative review aims to address the current knowledge about the impact of glucose-lowering agents used in T2DM on HF prevention, prognosis, and outcome.

show abstract

Section: Dpp-4 Inhibitorsmentioning

confidence: 99%

Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review

Nikolaidou,

Ventoulis,

Karakoulidis

et al. 2024

Medicina

View full text Add to dashboard Cite

show abstract

“…As a chronic disease accompanying constant elevated inflammation, diabetes has been demonstrated to be associated with some major changes in functional cardiac parameters early in LA and eventually LV and RV. FT-CMR can be used as a helpful tool to stratify the cardiovascular risk or to monitor the treatment-related risk of adverse cardiac remodeling [ 24 ]. CMR-encoded strains along with late gadolinium enhancement (LGE) have also been used as a novel screening tool for the detection of silent MI in type 2 diabetes, outperforming ECG criteria in terms of accuracy [ 25 ].…”

Section: Diabetesmentioning

confidence: 99%

Feature tracking cardiac magnetic resonance imaging to assess cardiac manifestations of systemic diseases

et al. 2023

View full text Add to dashboard Cite

Feature-tracking cardiac magnetic resonance (FT-CMR), with the ability to quantify myocardial deformation, has a unique role in the evaluation of subclinical myocardial abnormalities. This review aimed to evaluate the clinical use of cardiac FT-CMR-based myocardial strain in patients with various systemic diseases with cardiac involvement, such as hypertension, diabetes, cancer-therapy-related toxicities, amyloidosis, systemic scleroderma, myopathies, rheumatoid arthritis, thalassemia major, and coronavirus disease 2019 (COVID-19). We concluded that FT-CMR-derived strain can improve the accuracy of risk stratification and predict cardiac outcomes in patients with systemic diseases prior to symptomatic cardiac dysfunction. Furthermore, FT-CMR is particularly useful for patients with diseases or conditions which are associated with subtle myocardial dysfunction that may not be accurately detected with traditional methods. Compared to patients with cardiovascular diseases, patients with systemic diseases are less likely to undergo regular cardiovascular imaging to detect cardiac defects, whereas cardiac involvement in these patients can lead to major adverse outcomes; hence, the importance of cardiac imaging modalities might be underestimated in this group of patients. In this review, we gathered currently available data on the newly introduced role of FT-CMR in the diagnosis and prognosis of various systemic conditions. Further research is needed to define reference values and establish the role of this sensitive imaging modality, as a robust marker in predicting outcomes across a wide spectrum of patients.

show abstract

Relationship between saxagliptin use and left ventricular diastolic function assessed by cardiac MRI

Wong,

Ismail,

Connelly

et al. 2023

Acta Diabetol

View full text Add to dashboard Cite

The effects of saxagliptin on cardiac structure and function using cardiac MRI (SCARF)

Cited by 3 publications

References 30 publications

Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review

Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review

Feature tracking cardiac magnetic resonance imaging to assess cardiac manifestations of systemic diseases

Relationship between saxagliptin use and left ventricular diastolic function assessed by cardiac MRI

Contact Info

Product

Resources

About